What are the key takeaways from this BioCentury This Week episode?

Key insights include: **Korean Biotech Innovation Profile:** BioCentury's deal analysis from the past two years shows South Korean biotechs rank second in Asia after China for deal volume, with a notable distinction: first-in-class assets outnumber follow-on assets in product deals. Companies are taking deliberate target, biology, and modality risk across eight distinct modalities — the only viable path for markets too small to support me-too strategies.; **Intra-Asia Deal Strategy:** Half of Korean biotech deals over the analyzed period were struck between companies within Asia — Korea-to-Japan or intra-Korea partnerships. Biotechs should treat regional Asian partnerships as a structured first step toward global commercialization, using them to build asset value and combine platform technologies before pursuing Western licensing or partnership deals.; **Cross-Border Clinical Data Portability:** China's personal data regulations create a persistent bottleneck in due diligence — acquirers cannot remotely verify data integrity and must send staff on-site to individual trial sites. Biotech dealmakers should proactively structure data access protocols and portability frameworks into partnership agreements upfront, particularly for assets with Chinese trial data, to avoid deal delays.

What did Yating le and Reija Zhao discuss on BioCentury This Week?

BioCentury and Bay Helix's fifth East-West BioPharma Summit in Seoul surfaces key findings on South Korean biotech's rise, including deal flow data showing more first-in-class than follow-on assets, clinical trial competitiveness, cross-border data transfer barriers, and investor mindset gaps between Asian and Western markets. Key topics include: **Korean Biotech Innovation Profile:** BioCentury's deal analysis from the past two years shows South Korean biotechs rank second in Asia after China for deal volume, with a notable distinction: first-in-class assets outnumber follow-on assets in product deals. Companies are taking deliberate target, biology, and modality risk across eight distinct modalities — the only viable path for markets too small to support me-too strategies.; **Intra-Asia Deal Strategy:** Half of Korean biotech deals over the analyzed period were struck between companies within Asia — Korea-to-Japan or intra-Korea partnerships. Biotechs should treat regional Asian partnerships as a structured first step toward global commercialization, using them to build asset value and combine platform technologies before pursuing Western licensing or partnership deals..

How long is this episode of BioCentury This Week?

This episode is 26 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

BioCentury This Week

Ep. 354 - East-West Summit Takeaways

March 14, 2026

26 min episode · 2 min read

Yating le,Reija Zhao,Simone Fishburne

Episode

26 min

Read time

2 min

Topics

Productivity, Health & Wellness, Relationships

AI-Generated Summary

Published Mar 15, 2026

Key Takeaways

✓Korean Biotech Innovation Profile: BioCentury's deal analysis from the past two years shows South Korean biotechs rank second in Asia after China for deal volume, with a notable distinction: first-in-class assets outnumber follow-on assets in product deals. Companies are taking deliberate target, biology, and modality risk across eight distinct modalities — the only viable path for markets too small to support me-too strategies.
✓Intra-Asia Deal Strategy: Half of Korean biotech deals over the analyzed period were struck between companies within Asia — Korea-to-Japan or intra-Korea partnerships. Biotechs should treat regional Asian partnerships as a structured first step toward global commercialization, using them to build asset value and combine platform technologies before pursuing Western licensing or partnership deals.
✓Cross-Border Clinical Data Portability: China's personal data regulations create a persistent bottleneck in due diligence — acquirers cannot remotely verify data integrity and must send staff on-site to individual trial sites. Biotech dealmakers should proactively structure data access protocols and portability frameworks into partnership agreements upfront, particularly for assets with Chinese trial data, to avoid deal delays.
✓Asian Investor Mindset Gap: Asian VC and PE firms, even those focused on healthcare, frequently hold hospital assets alongside drug development portfolios — a structural difference from US healthcare-specialist investors. Western biotechs seeking Asian capital should expect later-stage asset preferences and deal structures that retain Greater China rights and marketing authorization holder status to satisfy local IPO obligations.
✓Korea's Two Core Bottlenecks: Billy Cho identified two specific constraints limiting Korea's biotech trajectory: capital access through to value inflection points, and insufficient in-country expertise in global clinical strategy. Companies and ecosystem builders targeting Korea should prioritize building clinical operations talent with multinational trial experience and connecting Korean biotechs to global CRO and regulatory networks.

What It Covers

BioCentury and Bay Helix's fifth East-West BioPharma Summit in Seoul surfaces key findings on South Korean biotech's rise, including deal flow data showing more first-in-class than follow-on assets, clinical trial competitiveness, cross-border data transfer barriers, and investor mindset gaps between Asian and Western markets.

Key Questions Answered

•Korean Biotech Innovation Profile: BioCentury's deal analysis from the past two years shows South Korean biotechs rank second in Asia after China for deal volume, with a notable distinction: first-in-class assets outnumber follow-on assets in product deals. Companies are taking deliberate target, biology, and modality risk across eight distinct modalities — the only viable path for markets too small to support me-too strategies.
•Intra-Asia Deal Strategy: Half of Korean biotech deals over the analyzed period were struck between companies within Asia — Korea-to-Japan or intra-Korea partnerships. Biotechs should treat regional Asian partnerships as a structured first step toward global commercialization, using them to build asset value and combine platform technologies before pursuing Western licensing or partnership deals.
•Cross-Border Clinical Data Portability: China's personal data regulations create a persistent bottleneck in due diligence — acquirers cannot remotely verify data integrity and must send staff on-site to individual trial sites. Biotech dealmakers should proactively structure data access protocols and portability frameworks into partnership agreements upfront, particularly for assets with Chinese trial data, to avoid deal delays.
•Asian Investor Mindset Gap: Asian VC and PE firms, even those focused on healthcare, frequently hold hospital assets alongside drug development portfolios — a structural difference from US healthcare-specialist investors. Western biotechs seeking Asian capital should expect later-stage asset preferences and deal structures that retain Greater China rights and marketing authorization holder status to satisfy local IPO obligations.
•Korea's Two Core Bottlenecks: Billy Cho identified two specific constraints limiting Korea's biotech trajectory: capital access through to value inflection points, and insufficient in-country expertise in global clinical strategy. Companies and ecosystem builders targeting Korea should prioritize building clinical operations talent with multinational trial experience and connecting Korean biotechs to global CRO and regulatory networks.

Notable Moment

Several US and European VCs attending the Seoul summit for the first time expressed surprise that Korean biotech company presentations were indistinguishable in sophistication from US biotech pitches — a perception shift that prompted at least one investor to commit to quarterly visits to the region.

Know someone who'd find this useful?

Episode Transcript

Welcome to a special edition of the BioSentry this week podcast. I'm Jeff Cranmer, executive editor here at BioSentry. And today, we bring you BioSentry this week from Seoul, where BioCentury and Bay Helix are hosting our fifth East West BioPharma Summit. Today, special guest, Yating Le, director of business development and licensing at Merck Group from Germany, and Reija Zhao, VP of clinical analytics, China at Cadia are joining VP and editor in chief, Simone Fishburne, and Josh Berlin, the illustrious Josh Berlin. Oh, you got an illustrious this time. I'm a big call of course. Yeah. Yeah. I've noticed that Josh feels a little, you know, a little slighted when Steven, you know, just keeps praise upon you, Simone. So Yeah. I get that a lot. Yeah. We're going to talk about some of the key takeaways from three days of in-depth panel discussions, one on one meetings, presenting company presentations, networking, and some very, very bad karaoke last night of which I was perhaps the guiltiest party, and, of course, kimchi in its many delicious forms. Simone, what were your key takeaways? Well, first of all, Jeff, I just have to ask because I was not at the session with the karaoke last night, and will I be able to find it on TikTok? I'm afraid I've been sent several, several videos already. I know some songs. Part of the record. Well, we always like to give props to Brian Denker, who's here. He's our one of the men who makes our conferences go, and, apparently, someone's created a compilation of all the songs Brian sang. So, hopefully, that overshadows whatever horror I, I did. Alright. Well, we'll be playing that on a future podcast. Right, Josh? I I think so. And, you know, we should give credit, I think, to Korea Bio, one of our regional hosts. They were certainly better at the karaoke, I think, than the BioCentury team. That's true. They they got a little more practice, Iyo and and and her colleagues. Shout out to Iyo who, got me to sing for the first time in, since the last time I was in Seoul, actually. So, well, let's let's dig in here. We've got a lot of great stuff to talk about. Simone, what's top of mind for you coming out of this week? Well, I think probably top of mind, you gotta talk about energy. Right? I think that there's just been a tremendous amount of energy here. I want to sort of draw what we typically do is, of course, draw a few threads that have come in terms of take homes during these last few days. So I think if I go back to the scene setter, which sort of launched the conference, a few themes came up there that I think we could discuss and that sort of played out over the next few days. So in that scene setter, what we had done was we really wanted to …

Get the full transcript (4,552 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all BioCentury This Week transcripts →